PART I Overview Immunovant is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402, a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of tot...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-05-29 | 2025-03-31 | 0001764013-25-000092 | EDGAR | 99K words |
| 2024-05-29 | 2024-03-31 | 0001764013-24-000109 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001764013-23-000065 | EDGAR | — |
| 2022-06-08 | 2022-03-31 | 0001764013-22-000059 | EDGAR | — |
| 2021-06-01 | 2021-03-31 | 0001764013-21-000052 | EDGAR | — |
| 2020-06-29 | 2020-03-31 | 0000950123-20-006444 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001764013-26-000101 | EDGAR | — |
| 2026-02-06 | 2025-12-31 | 0001764013-26-000011 | EDGAR | 20K words |
| 2025-11-10 | 2025-09-30 | 0001764013-25-000149 | EDGAR | — |
| 2025-08-11 | 2025-06-30 | 0001764013-25-000129 | EDGAR | — |
| 2025-02-06 | 2024-12-31 | 0001764013-25-000026 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001764013-24-000184 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001764013-24-000148 | EDGAR | — |
| 2024-02-12 | 2023-12-31 | 0001764013-24-000026 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001764013-23-000133 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001764013-23-000092 | EDGAR | — |
| 2023-02-03 | 2022-12-31 | 0001764013-23-000022 | EDGAR | — |
| 2022-11-04 | 2022-09-30 | 0001764013-22-000140 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001764013-26-000100 | EDGAR | — |
| 2026-02-06 | 0001764013-26-000010 | EDGAR | 3K words |
| 2025-12-12 | 0001193125-25-317577 | EDGAR | — |
| 2025-12-11 | 0001193125-25-314994 | EDGAR | — |
| 2025-11-21 | 0001764013-25-000153 | EDGAR | — |
| 2025-11-10 | 0001764013-25-000148 | EDGAR | — |
| 2025-09-03 | 0001764013-25-000136 | EDGAR | — |
| 2025-08-28 | 0001764013-25-000132 | EDGAR | — |
| 2025-08-11 | 0001764013-25-000128 | EDGAR | — |
| 2025-07-29 | 0001764013-25-000121 | EDGAR | — |
133 total filings indexed. 105 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001764013 |
| Ticker | IMVT |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.immunovant.com |
| Listed | 2019-06-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/IMVT (~200 tokens, structured JSON with cryptographic provenance)